Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$1.54 - $4.28 $485,163 - $1.35 Million
-315,041 Reduced 84.41%
58,202 $90,000
Q2 2022

Aug 12, 2022

BUY
$1.8 - $3.39 $671,837 - $1.27 Million
373,243 New
373,243 $1.05 Million

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $247M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Eam Investors, LLC Portfolio

Follow Eam Investors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eam Investors, LLC with notifications on news.